Pharmacophore modeling and 3D QSAR studies for prediction of matrix metalloproteinases inhibitory activity of hydroxamate derivatives
Dharmender Rathee, Viney Lather, Harish Dureja
Abstract
In order to develop potent inhibitors of matrix metalloproteinase (MMP-2 and MMP-9) as anticancer agents, pharmacophore modeling and three-dimensional quantitative structure–activity relationship (3D-QSAR) models were established using PHASE 3.0. A pharmacophore 5-point (AAARR) model was developed for the studied dataset and the generated model was used to derive the predictive atom-based 3D-QSAR models. After identifying a valid hypothesis, we developed 3D-QSAR models applying the PLS algorithm. The selected 3D-QSAR models were suggestive of the vitality of the electron-withdrawing feature for the MMPs inhibitory potential. In addition, hydrophobic groups, hydrogen bond donor groups, positive ionic and negative ionic features also positively contributed to the MMPs inhibitory potential along with the electron-withdrawing feature. The developed models were statistically robust (MMP-2 Q2 = 0.51; pred R2 = 0.67; MMP-9 Q2 = 0.59; pred R2 = 0.77). The QSAR results help in identifying a relationship between structural features of hydroxamate derivatives and their activities which could be useful to design newer MMP inhibitors.
Keywords
References
Combs, 2007
A.P. Combs
Structure-based drug design of new leads for phosphatase research
Investigational Drugs, 10 (2) (2007), pp. 112-115
Coumar et al., 2009
M.S. Coumar, J.S. Leou, P. Shukla, J.S. Wu, A.K. Dixit, W.H. Lin, et al.
Structure-based drug design of novel Aurora kinase A inhibitors: Structural basis for potency and specificity
Journal of Medicinal Chemistry, 52 (2009), pp. 1050-1062
Dixon et al., 2006
S.L. Dixon, A.M. Smondyrev, E.H. Knoll, S.N. Rao, D.E. Shaw, R.A. Friesner
PHASE: A new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results
Journal of Computer Aided Molecular Design, 20 (2006), pp. 647-671
Dureja et al., 2007
H. Dureja, V. Kumar, S. Gupta, A.K. Madan
Topochemical models for the prediction of lipophilicity of 1,3-disubstituted propan-2-one analogs
Journal of Theoretical and Computational Chemistry, 6 (2007), pp. 435-448
Egeblad and Werb, 2002
M. Egeblad, Z. Werb
New functions for the matrix metalloproteinases in cancer progression
Nature Reviews Cancer, 2 (2002), pp. 161-174
Folkman, 1971
J. Folkman
Tumor angiogenesis: Therapeutic implications
New England Journal of Medicine, 285 (1971), pp. 1182-1186
Guner, 2000
O.F. Guner
Pharmacophore perception, development and use in drug design
International University Line, San Diego, CA, USA (2000)
Gupta, 2015
S.P. Gupta
QSAR studies on hydroxamic acids: A fascinating family of chemicals with a wide spectrum of activities
Chemical Reviews, 115 (2015), pp. 6427-6490
Johnson et al., 1998
L.L. Johnson, R. Dyer, D.J. Hupe
Matrix metalloproteinases
Current Opinion in Chemical Biology, 2 (1998), pp. 466-471
Katritzky et al., 1996
A.R. Katritzky, L. Mu, V.S. Lobanov, M. Karelson
Correlation of boiling points with molecular structure. 1. A training set of 298 diverse organics and a test set of 9 simple inorganics
Journal of Physical Chemistry, 100 (1996), pp. 10400-10407
Khan et al., 2010
A. Khan, A. Prakash, D. Kumar, A. Rawat, R. Srivastava, R. Srivastava
Virtual screening and pharmacophore studies for ftase inhibitors using Indian plant anticancer compounds database
Bioinformation, 5 (2010), pp. 62-66
Kontogiorgis et al., 2005
C.A. Kontogiorgis, P. Papaioannou, D.J. Hadjipavlou-Litina
Matrix metalloproteinase inhibitors: A review on pharmacophore mapping and (Q)SARs results
Current Medicinal Chemistry, 12 (2005), pp. 339-355
Lather et al., 2008
V. Lather, R. Kristam, J.S. Singh, R. Kristam, N.A. Karthikeyan, V.N. Balaji
QSAR models for prediction of glycogen synthase kinase-3b inhibitory activity of indirubin derivatives
QSAR Combinatorial Science, 27 (6) (2008), pp. 718-728
Li et al., 2003
J. Li, Y.P. Zhang, R.S. Kirsner
Angiogenesis in wound repair: Angiogenic growth factors and the extracellular matrix
Microscopy Research & Technique, 60 (2003), pp. 107-114
Liekens et al., 2001
S. Liekens, E.D. Clercq, J. Neyts
Angiogenesis: Regulators and clinical applications
Biochemical Pharmacology, 61 (2001), pp. 253-270
Mori et al., 2013
M. Mori, A. Massaro, V. Calderone, M. Fragai, C. Luchinat, A. Mordini
Discovery of a new class of potent MMP inhibitors by structure based optimization of the arylsulfonamide scaffold
ACS Medicinal Chemistry Letters, 4 (2013), pp. 565-569
Morphy et al., 1995
J.R. Morphy, T.A. Millican, J.R. Porter
Matrix metalloproteinase inhibitors: Current status
Current Medicinal Chemistry, 2 (1995), pp. 743-762
Mustata et al., 2011
G. Mustata, M. Li, N. Zevola, A. Bakan, L. Zhang, M. Epperly, et al.
Development of small-molecule PUMA inhibitors for mitigating radiation-induced cell death
Current Topics in Medicinal Chemistry, 11 (2011), pp. 281-290
Nirmala et al., 2016
G. Nirmala, Y.B. Adimulam, P. Seetharamaiah
P.V. Lakshmi, et al. (Eds.), Computational intelligence techniques in health care. Springer briefs in forensic and medical bioinformatics (2016)
Phase, 2008
Phase
Version 3.0
Schrodinger LLC, New York, NY (2008)
Rathee et al., 2013
D. Rathee, M. Thanki, S. Bhuva, S. Anandjiwala, R. Agrawal
Iridoid glycosides-Kutkin, Picroside I, and Kutkoside from Picrorrhiza kurroa Benth inhibits the invasion and migration of MCF-7 breast cancer cells through the down regulation of matrix metalloproteinases
Arabian Journal of Chemistry, 6 (2013), pp. 49-58
Roy et al., 2001
K. Roy, D.K. Pal, A.U. De, C. Sengupta
QSAR of matrix metalloproteinase inhibitor N-[(substituted phenyl)sulfonyl]-N-4-nitrobenzylglycine hydroxamates using LFER model
Drug Design and Discovery, 17 (4) (2001), pp. 315-323
Scozzafava and Supuran, 2000
A. Scozzafava, C.T. Supuran
Protease inhibitors: Synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties
Journal of Medicinal Chemistry, 43 (2000), pp. 1858-1865
Skiles et al., 2001
J.W. Skiles, N.C. Gonnella, A.Y. Jeng
The design, structure, and therapeutic application of matrix metalloproteinase inhibitors
Current Medicinal Chemistry, 8 (2001), pp. 425-474
Stephen et al., 2001
H. Stephen, M. Nicolas, G. Cécile, V. Martin
N-aryl sulfonyl homocysteine hydroxamate inhibitors of matrix metalloproteinases: Further probing of the S1, S1, and S2 pockets
Journal of Medicinal Chemistry, 44 (2001), pp. 3066-3073
Stetler-Stevenson, 1999
W.G. Stetler-Stevenson
Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention
Journal of Clinical Investigation, 103 (1999), pp. 1237-1241
Subramaniam et al., 2009
R. Subramaniam, S. Malik, D.K. Srivastava
Natural products as inhibitors of matrix metalloproteinases
Natural products: Chemistry, biochemistry and pharmacology, Narosa Publishing House (2009), pp. 54-79
Summers and Davidsen, 1998
J.B. Summers, S.K. Davidsen
Matrix metalloproteinase inhibitors and cancer
Annual Reports in Medicinal Chemistry, 33 (1998), pp. 131-140
van Montfort and Workman, 2009
R.L. van Montfort, P. Workman
Structure-based design of molecular cancer therapeutics
Trends in Biotechnology, 27 (2009), pp. 315-328
Vihinen and Kähäri, 2002
P. Vihinen, V.M. Kähäri
Matrix metalloproteinases in cancer: Prognostic markers and therapeutic targets
International Journal of Cancer, 99 (2002), pp. 157-166
Weinstat-Saslow and Steeg, 1994
D. Weinstat-Saslow, P.S. Steeg
Angiogenesis and colonization in the tumor metastatic process: Basic and applied advances
FASEB Journal, 8 (1994), pp. 401-407
Wilson and Muftuoglu, 2012
G.M. Wilson, Y. Muftuoglu
Computational strategies in cancer drug discovery
Advances in Cancer Management (2012), pp. 237-254
Wold, 1991
S. Wold
Validation of QSAR's
Quantitative Structure-Activity Relationships, 10 (1991), pp. 191-193
Yu and Stamenkovic, 2000
Q. Yu, I. Stamenkovic
Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis
Genes & Development, 14 (2000), pp. 163-176
Zask et al., 1996
A. Zask, J.I. Levin, L.M. Killar, J.S. Skotnicki
Inhibition of matrix metalloproteinases: Structure based design
Current Pharmaceutical Design, 2 (1996), pp. 624-661
Zheng et al., 2008
J. Zheng, R. Wen, D. Guillaume
Three-dimensional quantitative structure–activity relationship (CoMFA and CoMSIA) studies on galardin derivatives as gelatinase A (matrix metalloproteinase 2) inhibitors
Journal of Enzyme Inhibition and Medicinal Chemistry, 23 (4) (2008), pp. 445-453
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email